Lazard has appointed David Krap as Managing Director and Co-Head of its European Consumer, Retail & Leisure division. Krap brings over 20 years of M&A advisory experience, especially in food, beverage, and consumer health sectors, joining from J.P. Morgan where he held a senior role. His appointment supports Lazard's 2030 strategy to grow its senior advisory talent and strengthen its European platform. Based in London, Krap will help expand Lazard's advisory capabilities and client relationships in the consumer sector across Europe.
David Krap's appointment at Lazard offers context for readers. For those following Financials-sector US stocks on Pluang, 113 of 142 rose and 28 fell today. Notable movers include MRSH at USD 188.80 (+5.83%), BLK at USD 1,135.11 (+5.71%), and IBN at USD 29.88 (+5.70%), as of Oct 19, 2026 11:21 WIB.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
